(at least 50% reduction in seizure frequency) in double-blind, placebo-controlled trials in Lennox-Gastaut syndrome

Seizure type Felbamate vs. Placebo Lamotrigine vs. Placebo Topiramate vs. Placebo
Total seizures 50% vs. 11%*    
All major seizures (drop attacks plus tonic-clonic)   33% vs. 16%* 33% vs. 8%*
Drop attack or atonic seizures 57% vs. 9%* 37* vs. 22%* 28% vs. 14%
Tonic-clonic seizures 60% vs. 23%* 43% vs. 20%*  

*P < .05

Adapted from: Glauser TA and Morita DA. Lennox-Gastaut syndrome. In: Devinsky O and Westbrook LE, eds. Epilepsy and Developmental Disabilities. Boston: Butterworth-Heinemann; 2001;73. With permission from Elsevier (www.elsevier.com).

Authored By: 
TA Glauser
DA Morita
Reviewed By: 
Steven C. Schachter MD
Friday, April 30, 2004